Invivyd (IVVD) Gains from Sales and Divestitures (2021 - 2025)
Invivyd posted quarterly Gains from Sales and Divestitures of $561000.0 for Q4 2025, little changed on a QoQ basis from $561000.0 in Q3 2025.
Invivyd (IVVD) has 4 years of Gains from Sales and Divestitures data on file, last reported at $561000.0 in Q4 2025.
- For the quarter ending Q4 2025, Gains from Sales and Divestitures changed N/A year-over-year to $561000.0; the trailing twelve-month figure through Dec 2025 stood at $561000.0 (changed N/A YoY), and the FY2025 full-year result was $561000.0, changed N/A from the prior year.
- Gains from Sales and Divestitures for Q4 2025 stood at $561000.0, roughly flat from $561000.0 in the prior quarter.
- Across five years, Gains from Sales and Divestitures topped out at $2.0 million in Q4 2021 and bottomed at $60055.0 in Q1 2023.
- The 4-year median for Gains from Sales and Divestitures is $511049.0 (2022), against an average of $644791.0.
- The widest annual swing landed in 2022, when Gains from Sales and Divestitures plunged 67.75%; it then plunged 86.84% in 2023.
- A 4-year view of Gains from Sales and Divestitures shows it stood at $2.0 million in 2021, then tumbled by 72.04% to $571105.0 in 2022, then sank by 86.84% to $75166.0 in 2023, then soared by 646.35% to $561000.0 in 2025.
- The last three Gains from Sales and Divestitures figures came in at $561000.0 (Q4 2025), $561000.0 (Q3 2025), and $75166.0 (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Invivyd | 208.38 Mn | -18.31 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 561,000.00 |
| Dec 31, 2025 | 561,000.00 |
| Sep 30, 2025 | 561,000.00 |
| Sep 30, 2025 | 561,000.00 |
| Dec 31, 2023 | 75,166.00 |
| Dec 31, 2023 | 75,166.00 |
| Sep 30, 2023 | 75,165.00 |
| Sep 30, 2023 | 75,165.00 |
| Jun 30, 2023 | 75,165.00 |
| Jun 30, 2023 | 75,165.00 |
| Mar 31, 2023 | 60,055.00 |
| Mar 31, 2023 | 60,055.00 |
| Dec 31, 2022 | 571,105.00 |
| Dec 31, 2022 | 571,105.00 |
| Sep 30, 2022 | 511,049.00 |
| Sep 30, 2022 | 511,049.00 |
| Jun 30, 2022 | 450,995.00 |
| Jun 30, 2022 | 450,995.00 |
| Mar 31, 2022 | 266,858.00 |
| Mar 31, 2022 | 266,858.00 |
| Dec 31, 2021 | 2.04 Mn |
| Dec 31, 2021 | 2.04 Mn |
| Sep 30, 2021 | 1.73 Mn |
| Sep 30, 2021 | 1.73 Mn |
| Jun 30, 2021 | 1.40 Mn |
| Jun 30, 2021 | 1.40 Mn |